X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1894) 1894
Book Review (300) 300
Publication (80) 80
Book Chapter (8) 8
Book / eBook (3) 3
Conference Proceeding (3) 3
Dissertation (3) 3
Newspaper Article (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1631) 1631
humans (1123) 1123
male (827) 827
animals (699) 699
glucosides - therapeutic use (621) 621
diabetes mellitus, type 2 - drug therapy (598) 598
female (584) 584
glucosides - pharmacology (523) 523
pharmacology & pharmacy (477) 477
hypoglycemic agents - therapeutic use (422) 422
glucosides - adverse effects (417) 417
middle aged (417) 417
type 2 diabetes (384) 384
diabetes (356) 356
sodium-glucose transporter 2 - antagonists & inhibitors (351) 351
glucose (335) 335
glucosides - administration & dosage (331) 331
benzhydryl compounds - therapeutic use (322) 322
rats (320) 320
adult (303) 303
mice (291) 291
hypoglycemic agents - adverse effects (286) 286
endocrinology & metabolism (278) 278
aged (272) 272
double-blind (266) 266
dapagliflozin (255) 255
treatment outcome (251) 251
analysis (245) 245
benzhydryl compounds - adverse effects (230) 230
glucosides (230) 230
care and treatment (209) 209
double-blind method (204) 204
diabetes mellitus, type 2 - blood (195) 195
hypoglycemic agents - administration & dosage (192) 192
metformin (192) 192
dextrose (191) 191
dose-response relationship, drug (190) 190
sglt2 inhibitor (188) 188
blood glucose - drug effects (179) 179
blood glucose - metabolism (177) 177
diabetes mellitus (171) 171
canagliflozin (166) 166
drug therapy, combination (162) 162
oxidative stress (162) 162
chemistry, medicinal (158) 158
biochemistry & molecular biology (155) 155
benzhydryl compounds - administration & dosage (154) 154
empagliflozin (153) 153
glucosides - chemistry (151) 151
insulin (147) 147
safety (147) 147
glycosides (146) 146
inflammation (146) 146
hypoglycemic agents - pharmacology (144) 144
mellitus (141) 141
toxicology (140) 140
clinical trials (139) 139
glucosides - pharmacokinetics (139) 139
research (135) 135
inadequate glycemic control (133) 133
glycemic control (131) 131
food science & technology (128) 128
hyperglycemia (128) 128
rodents (127) 127
drug therapy (123) 123
health aspects (122) 122
risk factors (121) 121
internal medicine (120) 120
rats, sprague-dawley (120) 120
diabetes mellitus, type 2 - complications (119) 119
plant extracts - pharmacology (119) 119
plant sciences (117) 117
in-vitro (113) 113
metabolism (112) 112
flavonoids (111) 111
thiophenes - therapeutic use (110) 110
glycated hemoglobin a - metabolism (109) 109
type 2 diabetes mellitus (109) 109
diabetes mellitus, type 2 - metabolism (108) 108
body weight - drug effects (107) 107
efficacy (107) 107
sodium (106) 106
sglt2 (105) 105
pharmacokinetics (103) 103
young adult (102) 102
blood pressure (101) 101
body weight (100) 100
benzhydryl compounds - pharmacology (99) 99
antioxidants (98) 98
apoptosis (98) 98
diabetes therapy (98) 98
disease models, animal (96) 96
integrative & complementary medicine (95) 95
phytotherapy (95) 95
sodium-glucose transporter 2 - metabolism (95) 95
blood pressure - drug effects (94) 94
medicine (93) 93
placebo-controlled trial (93) 93
physiological aspects (92) 92
hypoglycemic agents (91) 91
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1853) 1853
German (18) 18
Chinese (15) 15
Spanish (7) 7
French (4) 4
Japanese (3) 3
Danish (2) 2
Italian (2) 2
Czech (1) 1
Dutch (1) 1
Hungarian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetologia, ISSN 0012-186X, 12/2013, Volume 56, Issue 12, pp. 2582 - 2592
The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2 diabetes who were being... 
Sodium glucose co-transporter 2 (SGLT2) inhibitor | Medicine & Public Health | Human Physiology | Canagliflozin | Metabolic Diseases | Internal Medicine | Sitagliptin | Metformin | Type 2 diabetes mellitus | GLIPIZIDE | ADD-ON | SULFONYLUREA | DAPAGLIFLOZIN | MELLITUS | INADEQUATE GLYCEMIC CONTROL | DIET | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | 52-WEEK | INHIBITOR | Blood Pressure | Triazoles - administration & dosage | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Lipids | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucosides - adverse effects | Fasting | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Pyrazines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Body weight | Glucose | Comparative analysis | Dextrose | Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 384 - 393
Journal Article
DIABETES CARE, ISSN 0149-5992, 03/2014, Volume 37, Issue 3, pp. 740 - 750
Journal Article
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 355 - 364
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 4, pp. 323 - 334
Journal Article
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 420 - 428
Journal Article
Diabetes Care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 403 - 411
Journal Article
International Journal of Clinical Practice, ISSN 1368-5031, 12/2013, Volume 67, Issue 12, pp. 1267 - 1282
AimsCanagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double-blind,... 
BODY-WEIGHT | MEDICINE, GENERAL & INTERNAL | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | GLYCEMIC CONTROL | PLACEBO | ADD-ON | DAPAGLIFLOZIN | DOUBLE-BLIND | 2 SGLT2 INHIBITOR | IMPROVES INDEXES | BETA-CELL FUNCTION | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Weight Loss - drug effects | Metformin - adverse effects | Dose-Response Relationship, Drug | Young Adult | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Adult | Female | Blood Pressure - drug effects | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Glucosides - adverse effects | Insulin-Secreting Cells - physiology | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Sulfonylurea Compounds - adverse effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Canagliflozin | Glucosides - administration & dosage | Adolescent | Lipid Metabolism - drug effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Glucose metabolism | Care and treatment | Clinical trials | Hypoglycemic agents | Glucose | Cholesterol | Dextrose | Diabetes therapy | Patient safety | Pharmacology | Diabetes | Drug therapy | Clinical outcomes | Index Medicus | Endocrinology
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 22, pp. 2117 - 2128
Journal Article